[
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=042e6a7d293883c8e821bdcd9102bdf16b23ca7318f1e6792c8317cee8a0983f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733243580,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 131774952,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=042e6a7d293883c8e821bdcd9102bdf16b23ca7318f1e6792c8317cee8a0983f"
    }
  },
  {
    "ts": null,
    "headline": "J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids",
    "summary": "J&J files for FDA approval of Tremfya for plaque psoriasis and psoriatic arthritis indications in pediatric patients",
    "url": "https://finnhub.io/api/news?id=1caf7d3e3d9b33a4d129c81ae662da556772642b45d708b91de539b460e5229e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733234280,
      "headline": "J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids",
      "id": 131754580,
      "image": "https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "J&J files for FDA approval of Tremfya for plaque psoriasis and psoriatic arthritis indications in pediatric patients",
      "url": "https://finnhub.io/api/news?id=1caf7d3e3d9b33a4d129c81ae662da556772642b45d708b91de539b460e5229e"
    }
  },
  {
    "ts": null,
    "headline": "Harding Loevner Global Developed Markets Equity Q3 2024 Report",
    "summary": "Global markets advanced during the third quarter of 2024, with all regions posting gains. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=c425dbcba77923799cf4937ae9d3ebb720fc26b0c088ec8944d5b08b8510b85d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733226300,
      "headline": "Harding Loevner Global Developed Markets Equity Q3 2024 Report",
      "id": 131755093,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1921110478/image_1921110478.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Global markets advanced during the third quarter of 2024, with all regions posting gains. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=c425dbcba77923799cf4937ae9d3ebb720fc26b0c088ec8944d5b08b8510b85d"
    }
  },
  {
    "ts": null,
    "headline": "GLP-1 Drugs: Brand Companies Push FDA To Limit Compounding",
    "summary": "Brand companies who own GLP-1 products have been pushing the Food and Drug Administration to limit their compounding. On August 28, 2024, Eli Lilly and Company submitted a nomination to request that...",
    "url": "https://finnhub.io/api/news?id=d57faa86a4a1873d69751fdd2cad7459f18ac1e6ab2fdb056bfe2b5897264b9b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733209811,
      "headline": "GLP-1 Drugs: Brand Companies Push FDA To Limit Compounding",
      "id": 131750967,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Brand companies who own GLP-1 products have been pushing the Food and Drug Administration to limit their compounding. On August 28, 2024, Eli Lilly and Company submitted a nomination to request that...",
      "url": "https://finnhub.io/api/news?id=d57faa86a4a1873d69751fdd2cad7459f18ac1e6ab2fdb056bfe2b5897264b9b"
    }
  },
  {
    "ts": null,
    "headline": "Exclusive-Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms",
    "summary": "Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular weight-loss drug Wegovy over fears of falling behind rival Eli Lilly in the potentially huge market, two sources familiar with the plans told Reuters.  Officials at the Danish drugmaker have said Wegovy might be introduced in India in 2026 once regulatory approvals are in hand and there is sufficient supply.  More recently, Novo's India team proposed moving the launch to next year, around the same time Lilly is expected to introduce its weight-loss drug Mounjaro.",
    "url": "https://finnhub.io/api/news?id=34c0df988e56affada63d68b8082b82e6d30664abf197160382e0d41dbea2651",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733205772,
      "headline": "Exclusive-Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms",
      "id": 131746989,
      "image": "https://media.zenfs.com/en/reuters.com/32f378dd0c2978762c186dbccf5644f9",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular weight-loss drug Wegovy over fears of falling behind rival Eli Lilly in the potentially huge market, two sources familiar with the plans told Reuters.  Officials at the Danish drugmaker have said Wegovy might be introduced in India in 2026 once regulatory approvals are in hand and there is sufficient supply.  More recently, Novo's India team proposed moving the launch to next year, around the same time Lilly is expected to introduce its weight-loss drug Mounjaro.",
      "url": "https://finnhub.io/api/news?id=34c0df988e56affada63d68b8082b82e6d30664abf197160382e0d41dbea2651"
    }
  }
]